写的:
基于几十年的研究, we are starting to unravel complex inflammatory cell signalling pathways and uncover key drivers that cause an imbalance in immune-mediated diseases.
据估计，全世界有500万人患有狼疮1 和6.800万人患有炎症性肠病2, 众所周知的免疫介导性疾病, there is a significant need for new innovative therapies to help improve outcomes for these patients.
在免疫介导的疾病中精确靶向疾病驱动因子
摆脱了传统的逐步治疗方法, the next-wave of therapeutic discovery is embracing the potential that precision medicine can offer - ensuring the right patient, 吃对了药, 在适当的时候. We are rapidly building our knowledge of disease biomarkers to help differentiate patient subgroups within a single disease, 开发诊断测试和精准药物, 哪些是针对疾病的根本原因的.
什么是慢性病的精准医疗?
炎症性肠病
Our precision medicine approach in 炎症性肠病 (IBD) focuses on selecting distinct patient subpopulations through identifying biomarkers of disease. IBD is an umbrella term for conditions with chronic inflammation of the gastrointestinal tract and includes ulcerative colitis and Crohn’s disease. 到目前为止, 澳门第一赌城在线娱乐的核心研究集中在被称为白细胞介素的炎症细胞因子上, 已知在这些条件下会增加, so we can identify patients who are failing to respond to treatment or become intolerant over time3.
The pro-inflammatory cytokine interleukin 23 (IL-23) is a known driver of inflammation and is mainly secreted by activated macrophages and dendritic cells located in tissues like skin, 肺和肠粘膜3. IL-23 potently enhances local inflammation by increasing T helper (Th) cells which are responsible for many of the autoimmune responses in IBD. Crohn’s Disease is driven by a Th1/Th17 interaction where IL-23 plays a key part and this is supported by genome-wide association studies that have strongly connected IL-23 to the pathogenesis of Crohn’s Disease.
血液中IL-23的水平, 即使在疾病中升高, 用简单易用的技术很难检测到吗. 临床上需要一种替代的生物标志物来确定患者是否患有IL-23驱动的疾病. The effector cytokine IL-22 is a downstream product of IL-23 and has roles maintaining the integrity of the mucosal barrier and stimulating epithelial cell proliferation. 它也是IL-23活性的直接指标，因此具有作为疾病生物标志物的潜力3.
We believe that a significant reduction in IL-22 levels could be indicative of both disease activity and potential post-treatment disease modification. 与罗氏诊断公司合作, 澳门第一赌城在线娱乐目前正在研制一种精确的, non-invasive diagnostic test for IL-22 and exploring the interconnection between biomarker levels and clinical outcomes across a broad range of patients.
系统性红斑狼疮
系统性红斑狼疮 SLE是一种复杂的疾病, 一种慢性疾病，身体的免疫系统攻击身体任何部位的健康组织. 据估计，全世界至少有500万人患有狼疮1可表现为一系列症状，包括皮疹、关节疼痛、肿胀和发烧. 对狼疮的了解仍然很少，而且对身体的影响很大, 该病患者的情感和社会经济负担仍然很高4.
SLE涉及b细胞过度活跃, t细胞和树突状细胞, 以及炎性细胞因子如1型干扰素(IFN), IL-6和b细胞活化因子. Cytokines regulate and coordinate the overall inflammatory response and in people with SLE over production results in a prolonged autoimmune response, 导致受伤, 炎症和长期器官损伤5-10.
Research has shown an association between an elevated IFN gene signature and disease as well as a correlation between IFN protein levels and serological and clinical manifestations of SLE11. These data underscore our focus on IFN as a biomarker of SLE disease activity and is helping to guide our precision medicine approach. Research has shown that by measuring IFN mRNA levels instead of protein it was possible to detect an elevated IFN gene signature in over three quarters of adults in our patient cohort12. We’ve successfully deployed this blood-based biomarker test for IFN activity in clinical study programs to stratify patients with SLE and understand their underlying disease drivers12.
前进, our scientists are also investigating other immune-mediated diseases where an IFN gene signature may enrich for patient populations likely to benefit from targeted treatments and improve their disease outcomes.
为患者提供精准药物
在免疫介导性疾病方面，患者和卫生保健系统仍有巨大的需求未得到满足. Providing access to routine diagnostics and precision medicines targeted to the underlying disease will be a powerful enabler of better patient outcomes and more sustainable care. 创新融资, 监管和临床机制将是支持获取和吸收的必要条件. We are committed to working collaboratively with the immunology community to realise this potential and deliver precision medicine research to improve lives of those living with immune-mediated diseases.
